A Phase 3, Open Label, Multicenter, Baseline-Controlled Sequential Dose Titration Study Followed by a Fixed Dose Observation Period to Evaluate Pharmacokinetics, Efficacy and Safety of Mirabegron Prolonged-Release Microgranula Based Suspension in Children from 6 Months to Less Than 3 Years of Age with Neurogenic Detrusor Overactivity
Latest Information Update: 08 Mar 2025
At a glance
- Drugs Mirabegron (Primary)
- Indications Detrusor instability; Neurogenic bladder; Overactive bladder
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma Global Development
- 13 Jun 2024 Planned primary completion date changed from 30 Jun 2026 to 28 Feb 2025.
- 03 May 2024 Planned End Date changed from 31 Jul 2026 to 30 Jun 2026.
- 03 May 2024 Planned primary completion date changed from 31 Jul 2026 to 30 Jun 2026.